GHRP-6

01 · What it is

GHRP-6 is a synthetic hexapeptide and an agonist at the growth hormone secretagogue receptor GHS-R1a. It was the first of these compounds to be extensively studied in humans, and everything else in this family — GHRP-2, hexarelin, ipamorelin, ibutamoren — descends from it, either as a more potent analogue, a more selective one, or a non-peptide mimetic of its action ^3,4.

Its historical importance is easy to state and rarely stated: GHRP-6 is the compound that established that a synthetic peptide acting outside the GHRH system could release growth hormone at all. The receptor it acts on was named after the class it founded. That the endogenous ligand for that receptor — ghrelin — was not identified until years later is a detail worth keeping in view: these compounds were discovered before the system they act on was understood.

The clinical trajectory since is the interesting part. GHRP-6 was investigated as a diagnostic agent for growth hormone deficiency, and the investigators reported the result honestly: growth hormone response to GHRP-6 was lower in children with growth hormone deficiency than in normal children, but on an individual basis a considerable degree of overlap was observed between the two groups ². An overlapping distribution is a failed diagnostic test, and it was reported as such.

No efficacy trial of GHRP-6 in a treatment indication was identified during preparation of this guide. Its most active modern research line has nothing to do with growth hormone: a 2025 study developed a GHRP-6 hydrogel for acute kidney injury, reporting metabolic regulation involving spermidine, L-glutamine and acetyl-CoA in a mouse model ¹⁶.

As of September 2026 GHRP-6 holds no marketing authorisation from any regulator.

02 · Evidence at a glance

Evidence grade

Early Clinical — extensive human pharmacology; no efficacy trial

Structure

Synthetic hexapeptide; the founding compound of the growth hormone-releasing peptide class ^3,4

Molecular target

Growth hormone secretagogue receptor GHS-R1a ⁸

Historical position

First growth hormone-releasing peptide extensively studied in humans ³

Potency

Comparable to ipamorelin; lower than GHRP-2 ⁵

Selectivity

Not selective — releases ACTH, cortisol and prolactin alongside growth hormone ^3,4,5

Diagnostic performance in growth hormone deficiency

Considerable overlap between deficient and normal children on an individual basis ²

Efficacy trials in any treatment indication

None identified

Mechanism dependency

Requires both GHRH and somatostatin pathways ¹

Most active current research

Tissue protection, not endocrinology ¹⁶

Approval status

None, any jurisdiction

03 · Mechanism of action

A pathway that is not GHRH, and not independent of it either

GHRP-6 acts at the growth hormone secretagogue receptor, not the GHRH receptor. But the effect is not receptor-autonomous. In rats pretreated with antisera against GHRH and against somatostatin, intravenous GHRP-6 at 25 µg/kg produced growth hormone responses that depended on both systems, demonstrating that the peptide works through a combination of endogenous GHRH release and somatostatin withdrawal rather than by acting on somatotrophs in isolation ¹.

This is the mechanistic finding that explains the whole family. It is why GHRH plus GHRP produces more growth hormone than either alone, it is the basis for every combination protocol in this family, and it was established in 1995 by an antisera-depletion experiment — a proper mechanistic test.

The unknown factor problem

Reviewers writing at the height of this literature noted that the possibility that growth hormone-releasing peptides act via an unknown hypothalamic factor remained open ³. Later work identified ghrelin as the endogenous ligand for the receptor, but the question of whether that fully accounts for GHRP action has not been cleanly closed. In humans, the putative antagonist D-Lys-GHRP-6 did not modify the endocrine response to acylated ghrelin or to hexarelin ⁹, which is difficult to reconcile with a simple competitive single-receptor model.

A family of compounds whose canonical antagonist does not antagonise them in humans has an unresolved receptor pharmacology, and this is rarely acknowledged.

Non-selectivity

GHRP-6 stimulates adrenocorticotropic hormone, cortisol and prolactin alongside growth hormone ^3,4. The comparative pharmacology that characterised ipamorelin measured this directly: ipamorelin matched GHRP-6 for growth hormone release without the adrenocorticotropic and cortisol response GHRP-6 produced ⁵.

This is the property that motivated the development of everything that came after it.

Effects outside the growth hormone axis

The more interesting contemporary mechanism work concerns tissue protection. A GHRP-6 hydrogel improved outcomes in a mouse model of acute kidney injury, with metabolomic sequencing showing enrichment of spermidine, L-glutamine and acetyl-CoA — metabolites of amino acid and fatty acid pathways ¹⁶.

Whether this is growth hormone-dependent is not established, and the parallel with hexarelin’s CD36-mediated cardioprotection suggests these peptides may have a second biology the growth hormone framing obscures.

04 · Key research findings

Diagnostic testing, and an honest negative. GHRP-6 was evaluated as a test for growth hormone deficiency in children. Growth hormone response was lower in deficient children than in normal children, but on an individual basis considerable overlap was observed between the groups ².

A diagnostic test that cannot separate individuals is not a diagnostic test, and the investigators said so. Compare sermorelin, which cleared the same bar and earned an approval for exactly this use — the comparison is the most instructive thing on this page.

Mechanism. Antisera depletion in rats established that GHRP-6’s growth hormone response involves both GHRH and somatostatin ¹.

A clean experiment with a clear result, and the foundation of the combination rationale used across this family.

Comparative pharmacology. GHRP-6 released growth hormone in conscious swine with ED50 3.9 ± 1.4 nmol/kg and Emax 74 ± 7 ng GH/mL, closely comparable to ipamorelin, with GHRP-2 more potent than either — and unlike ipamorelin, GHRP-6 produced adrenocorticotropic and cortisol release ⁵.

Combined testing in metabolic disease. Growth hormone response to combined intravenous GHRH plus GHRP-6 was measured in patients with type 2 diabetes under euglycaemic and hyperglycaemic clamp conditions ⁷. In obesity, GHRP-6 and hexarelin elicited growth hormone responses greater than those evoked by GHRH but still lower than in lean subjects ⁶.

Careful physiological work characterising how the response behaves in metabolic disease — and none of it measures a clinical outcome.

Acute kidney injury. A GHRP-6 hydrogel improved outcomes in a mouse model, with metabolomic analysis identifying enrichment of spermidine, L-glutamine and acetyl-CoA ¹⁶.

The most recent primary research on this compound is a drug-delivery and tissue-protection study in a non-endocrine indication.

Chemistry. Peptidomimetic work has produced constrained GHRP-6 analogues for conformational studies ¹⁰, and enzymatic and serum stability profiles have been mapped for GHRP-6 alongside related doping-relevant peptides ¹⁵.

Detection. GHRP-6 has been detected in athlete urine samples ¹¹ and its urinary metabolites characterised after nasal administration ¹².

Efficacy trials. None identified in any treatment indication.

05 · Evidence overview

06 · Safety profile

Endocrine profile. GHRP-6 raises adrenocorticotropic hormone, cortisol and prolactin alongside growth hormone ^3,4,5. This is the compound’s principal safety consideration and it is intrinsic rather than incidental — it is what ipamorelin was designed to avoid.

Human data. Acute administration in endocrine and diagnostic studies, including in children being assessed for growth hormone deficiency ², in obesity ⁶ and in type 2 diabetes ⁷. These studies report the hormonal response rather than a safety profile, and none involved repeated dosing.

Class liability. Growth hormone antagonises insulin action, and glucose tolerance is the central metabolic consideration for any effective secretagogue ^13,14. The clamp studies in type 2 diabetes ⁷ characterise the growth hormone response under controlled glycaemia rather than the metabolic consequences of sustained administration.

What is genuinely unknown. Repeated administration in humans, in any population, for any duration — no such study exists. Cortisol and prolactin behaviour under sustained dosing, which is the question that most matters for this compound specifically. Toxicology of any kind: no repeat-dose, genotoxicity, reproductive or carcinogenicity programme was identified. Immunogenicity, unassessed. And whether the tissue-protective effects emerging in animal models ¹⁶ involve the growth hormone axis at all, which nobody has tested.

FDA’s stated basis for placing GHRP-6 in category 2 is that compounded drugs containing it may pose immunogenicity risk for certain routes of administration due to aggregation and peptide-related impurities, with limited safety-related information identified, and available data revealing concerns including potential effects on cortisol and increased blood glucose from decreased insulin sensitivity ¹⁷.

Those two concerns correspond to what the primary endocrine literature would predict ^3,4,5, which is a case where the regulatory characterisation and the science agree.

07 · US regulatory status

Current as of 6 September 2026. GHRP-6 is not approved as a drug in the United States or any other jurisdiction, and is not a controlled substance.

Growth hormone releasing peptide-6 was placed in category 2 of FDA’s interim bulk drug substances policy for 503B outsourcing facilities on 29 September 2023, and remains in the active category 2 table ¹⁷. GHRP-6 was not among the seven substances reviewed by the Pharmacy Compounding Advisory Committee in July 2026 ¹⁸.

Under the World Anti-Doping Code, growth hormone secretagogues are prohibited at all times. GHRP-6 has been detected in athlete urine samples using validated methods ¹¹, with metabolite targets established after nasal administration ¹². Competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. No efficacy trial exists in any treatment indication. The human literature is endocrine physiology and diagnostic testing. Nothing measures whether administering GHRP-6 improves anything a patient would notice.
2. Its one tested clinical application failed. As a diagnostic for growth hormone deficiency, individual responses overlapped considerably between deficient and normal children ². That is a negative result on the only clinical question GHRP-6 was formally asked.
3. Non-selectivity is a design flaw the field acknowledged by moving on. Cortisol and prolactin release alongside growth hormone ^3,4,5 is why ipamorelin exists. Using the founding compound rather than its selective successor forgoes the one improvement the field achieved.
4. All human data are acute. No repeated-dose study in humans was identified, so the effects that matter under chronic use — sustained cortisol elevation in particular — are entirely uncharacterised.
5. The receptor pharmacology has an unresolved problem. D-Lys-GHRP-6, the putative antagonist, did not modify endocrine responses to related agonists in humans ⁹. A family whose antagonist does not antagonise has a model that is incomplete.
6. No toxicology programme was identified in any species.
7. The most promising current findings are in a different field entirely. Tissue protection in acute kidney injury ¹⁶ is interesting, is in mice, uses a hydrogel formulation rather than the free peptide, and has no bearing on the reasons GHRP-6 is used.

09 · References

1. Conley LK, Teik JA, Deghenghi R, et al. Mechanism of action of hexarelin and GHRP-6: analysis of the involvement of GHRH and somatostatin in the rat. Neuroendocrinology. 1995;61(1):44–50.

   PMID 7731497 ↗

2. Pombo M, Leal-Cerro A, Barreiro J, et al. Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. J Pediatr Endocrinol Metab. 1996;9(Suppl 3):333–338.

   PMID 8887178 ↗

3. Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445–460.

   PMID 9186261 ↗

4. Camanni F, Ghigo E, Arvat E. Growth hormone-releasing peptides and their analogs. Front Neuroendocrinol. 1998;19(1):47–72.

   PMID 9465289 ↗

5. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561.

   PMID 9849822 ↗

6. Scacchi M, Pincelli AI, Cavagnini F. Growth hormone in obesity. Int J Obes Relat Metab Disord. 1999;23(3):260–271.

   PMID 10193871 ↗

7. Micic D, Kendereski A, Sumarac-Dumanovic M, Cvijovic G, Popovic V, Dieguez C, Casanueva F. Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp. Diabetes Res Clin Pract. 2004;63(1):37–45.

   PMID 14693411 ↗

8. Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005;26(3):346–360.

   PMID 15814848 ↗

9. Benso A, Prodam F, Lucatello B, et al. d-Lys-GHRP-6 does not modify the endocrine response to acylated ghrelin or hexarelin in humans. Neuropeptides. 2007;41(1):45–49.

   PMID 17112585 ↗

10. Doan ND, Hopewell R, Lubell WD. N-aminoimidazolidin-2-one peptidomimetics. Org Lett. 2014;16(8):2232–2235.

    PMID 24697286 ↗

11. Cox HD, Hughes CM, Eichner D. Detection of GHRP-2 and GHRP-6 in urine samples from athletes. Drug Test Anal. 2015;7(5):439–444.

    PMID 25809000 ↗

12. Semenistaya E, Zvereva I, Thomas A, Thevis M, Krotov G, Rodchenkov G. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, hexarelin, and ipamorelin. Drug Test Anal. 2015;7(10):919–925.

    PMID 25869809 ↗

13. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45–53.

    PMID 28400207 ↗

14. Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149–S159.

    PMID 32257855 ↗

15. González-López NM, Guerra-Acero-Turizo LM, Blanco-Medina I, et al. In-house standards derived from doping peptides: enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides. Biomed Chromatogr. 2023;37(12):e5741.

    PMID 37688464 ↗

16. Zhao X, Pan K, Li R, et al. Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation. J Nanobiotechnology. 2025;24(1):15.

    PMID 41327290 ↗

17. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Page current as of 22 April 2026. Regulatory document; no PMID.

    Source ↗

18. US Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Docket FDA-2025-N-6895. Regulatory document; no PMID.

    Source ↗